Dementia with Lewy bodies

Novel Sleep Biomarkers Linked to Neurodegenerative Disease

Retrieved on: 
Tuesday, April 20, 2021
Medical devices, Other Health, Health, Science, Research, Psychiatric diagnosis, Branches of biology, Cognitive disorders, Psychiatry, Learning disabilities, Biology, Aging-associated diseases, Dementia with Lewy bodies, Synucleinopathy, Dementia, Lewy body, Rapid eye movement sleep behavior disorder

b"\xe2\x80\x9cThe biomarkers were discovered with the company\xe2\x80\x99s Sleep Profiler\xe2\x84\xa2, while being used by National Institute of Health-funded research collaborators across seven U.S. institutions,\xe2\x80\x9d stated Daniel J. Levendowski, the studies\xe2\x80\x99 lead author.\nThe first biomarker, called Non-REM Sleep with Hypertonia, was pronounced in patients with Parkinson\xe2\x80\x99s disease, REM sleep behavior disorder and those with Dementia with Lewy Bodies or Parkinson\xe2\x80\x99s Disease Dementia, but limited in those with mild cognitive impairment, Alzheimer\xe2\x80\x99s Disease dementia or normal cognition.

Key Points: 
  • b"\xe2\x80\x9cThe biomarkers were discovered with the company\xe2\x80\x99s Sleep Profiler\xe2\x84\xa2, while being used by National Institute of Health-funded research collaborators across seven U.S. institutions,\xe2\x80\x9d stated Daniel J. Levendowski, the studies\xe2\x80\x99 lead author.\nThe first biomarker, called Non-REM Sleep with Hypertonia, was pronounced in patients with Parkinson\xe2\x80\x99s disease, REM sleep behavior disorder and those with Dementia with Lewy Bodies or Parkinson\xe2\x80\x99s Disease Dementia, but limited in those with mild cognitive impairment, Alzheimer\xe2\x80\x99s Disease dementia or normal cognition.
  • The second biomarker, Atypical Stage N3 Sleep, was found to be significantly greater in patients with synucleinopathies with dementia.
  • Both biomarkers exhibited the characteristics one would expect for the prodromal assessment of synucleinopathies.
  • Over 50,000 nights of Sleep Profiler\xe2\x84\xa2 data were acquired by sleep medicine professionals, neurologists, and researchers during the past two years.

Groundbreaking research award established to discover an accurate method of diagnosing Lewy body dementia

Retrieved on: 
Thursday, April 15, 2021
Cognitive disorders, Lewy body dementia, Psychiatric diagnosis, Branches of biology, Psychiatry, Dementia, Aging-associated diseases, Clinical medicine, Lewy body, Lewy, Dementia with Lewy bodies, Dementia with Lewy Bodies Consortium

Fox Foundation for Parkinson\'s Research and the American Academy of Neurology to establish its 2022 Cure One, Cure Many Award: A research award for early diagnosis of Lewy body dementia.

Key Points: 
  • Fox Foundation for Parkinson\'s Research and the American Academy of Neurology to establish its 2022 Cure One, Cure Many Award: A research award for early diagnosis of Lewy body dementia.
  • The hope is that this will lead to an accurate method of diagnosing the disease giving patients and their loved ones clarity about the prognosis.
  • "Shared pathology across Parkinson\'s disease and Lewy body dementia means that better understanding the biology of one can help advance research into the other, growing the impact of this program across diagnostic lines.
  • To learn more about the award and to see how you can help support this initiative, visit americanbrainfoundation.org/cocm\n'

$44 Million NIH Grant to See if Dementia Can Be Prevented

Retrieved on: 
Tuesday, April 6, 2021
Psychiatric diagnosis, Cognitive disorders, Learning disabilities, Psychiatry, Mind, Aging-associated diseases, Psychology, Neuropsychology, Dementia, Brain training, Dementia with Lewy bodies, Vascular dementia

This new grant furthers prior research, published as findings of the ACTIVE Study in 2017 , that showed a small amount of cognitive training significantly reduced the risk and incidence of dementia among older adults.

Key Points: 
  • This new grant furthers prior research, published as findings of the ACTIVE Study in 2017 , that showed a small amount of cognitive training significantly reduced the risk and incidence of dementia among older adults.
  • This study addresses the central question that most people have about brain training does training your brain reduce your chances of dementia?
  • Researchers reported an up to 48 percent reduction in dementia incidence among people who asked to complete up to 18 hours of training and an overall 29 percent reduction in dementia risk.
  • Its gratifying to see the NIH going the distance building on the established science of brain training to answer the crucial question of dementia prevention, Dr. Mahncke observed.

Cognition Therapeutics Publishes Evidence Identifying Receptor Integral in Parkinson’s Disease Pathology

Retrieved on: 
Monday, February 1, 2021
Branches of biology, Neurological disorders, Psychiatric diagnosis, Aging-associated diseases, Medical specialties, Geriatrics, Synucleinopathy, Parkinson's disease, Dementia with Lewy bodies, Lewy body, Multiple system atrophy, Neurodegeneration

In this publication, Cognition scientists identify the sigma-2 (-2) receptor as integral in the pathology of Parkinsons disease.

Key Points: 
  • In this publication, Cognition scientists identify the sigma-2 (-2) receptor as integral in the pathology of Parkinsons disease.
  • In Parkinsons disease, cumulative damage from a variety of stressors results in structural changes in the -synuclein protein.
  • Aggregates of -synuclein are strongly correlated with disease pathology in Parkinsons and related synucleinopathies such as dementia with Lewy bodies and multiple system atrophy.
  • Cognition Therapeutics, Inc. has discovered and is developing a pipeline of novel, disease modifying, oral drug candidates to treat a broad array of neurodegenerative and neuro-ophthalmic disorders.

Annovis Issued Patent for Method of Treating Parkinson’s Disease and Other Lewy Body Diseases

Retrieved on: 
Thursday, February 20, 2020
Psychiatric diagnosis, RTT, Branches of biology, Organ systems, Medicine, Cognitive disorders, Aging-associated diseases, Geriatrics, Neurodegeneration, Parkinson's disease, Dementia with Lewy bodies, Alzheimer's disease

BERWYN, Pa., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimers, Parkinsons and other neurodegenerative diseases, was issued a patent (US 10,383,851) in August 2019 for a method of treating Parkinsons disease, Lewy body dementia and other Lewy body diseases in humans by administering its lead compound, ANVS401.

Key Points: 
  • BERWYN, Pa., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimers, Parkinsons and other neurodegenerative diseases, was issued a patent (US 10,383,851) in August 2019 for a method of treating Parkinsons disease, Lewy body dementia and other Lewy body diseases in humans by administering its lead compound, ANVS401.
  • Maria Maccecchini, Ph.D., CEO of Annovis, commented, Based on discussions with the patent office, we have filed additional patent applications for each individual neurodegenerative disease that our drug targets.
  • ANVS401 is the lead compound in the Companys ongoing Phase 2a clinical trial for Alzheimers disease and in a planned Phase 2a trial for Parkinsons disease.
  • Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimers disease (AD), Parkinsons disease (PD) and Alzheimers in Down Syndrome (AD-DS).

United States Lewy Body Dementia Market Report 2019: Treatment, Pipeline, Epidemiology, Key Products, Valuations, Drug Sales and Market Shares 2014-2024 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 11, 2019
Health, Pharmaceutical, Lewy body dementia, Psychiatry, Abnormal psychology, Cognition, Lewy, Dementia, Lewy Body Dementia Association, Dementia with Lewy bodies

US Lewy Body Dementia Market and Competitive Landscape Highlights - 2019, provides comprehensive insights into Lewy Body Dementia pipeline products, Lewy Body Dementia epidemiology, Lewy Body Dementia market valuations and forecast, Lewy Body Dementia drugs sales and competitive landscape in the US.

Key Points: 
  • US Lewy Body Dementia Market and Competitive Landscape Highlights - 2019, provides comprehensive insights into Lewy Body Dementia pipeline products, Lewy Body Dementia epidemiology, Lewy Body Dementia market valuations and forecast, Lewy Body Dementia drugs sales and competitive landscape in the US.
  • The research is classified into seven sections- Lewy Body Dementia treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.
  • Lewy Body Dementia pipeline: Find out the products in clinical trials for the treatment of Lewy Body Dementia by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Lewy Body Dementia drugs: Identify key products marketed and prescribed for Lewy Body Dementia in the US, including trade name, molecule name, and company
    Lewy Body Dementia drugs sales: Find out the sales revenues of Lewy Body Dementia drugs in the US
    Lewy Body Dementia market valuations: Find out the market size for Lewy Body Dementia drugs in 2018 in the US.
  • Find out how the market advanced from 2014 and forecast to 2024
    Lewy Body Dementia drugs market share: Find out the market shares for key Lewy Body Dementia drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Lewy Body Dementia products
    View source version on businesswire.com: https://www.businesswire.com/news/home/20190711005308/en/

The Lewy Body Dementia Resource Center is Hosting an Exclusive Private Screening and Reception of Robin's Wish at Lincoln Center in New York

Retrieved on: 
Wednesday, July 10, 2019
Lewy body dementia, Comedians, Actors, Psychiatry, Lewy, Dementia, LBD, Robin Williams, Lewy Body Dementia Association, Dementia with Lewy bodies

NEW YORK, July 10, 2019 /PRNewswire/ --On Wednesday, July 17, 2019, the Lewy Body Dementia Resource Center will host a special exclusive screening of Robin's Wish .

Key Points: 
  • NEW YORK, July 10, 2019 /PRNewswire/ --On Wednesday, July 17, 2019, the Lewy Body Dementia Resource Center will host a special exclusive screening of Robin's Wish .
  • It explores the untold love story of his marriage to Susan Schneider Williams, his tragic suicide, and his experience coping with his undiagnosed Lewy Body Dementia.
  • The Lewy Body Dementia Resource Center offers loving support and information to caregivers of those suffering from Lewy Body Dementia.
  • The Lewy Body Dementia Resource Center was founded in an effort to ease the burden of caring for those suffering with LBD.

Lewy Body Dementia Clinical Trial Pipeline Highlights 2019 - Track Competition, Identify Partners, Formulate Business Development Strategies - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 12, 2019
Professional services, Consulting, Health, Lewy body dementia, Psychiatric diagnosis, Psychiatry, Medicine, RTT, Cognitive disorders, Learning disabilities, Dementia, Lewy, Clinical trial, Dementia with Lewy bodies

The "Global Lewy Body Dementia Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Lewy Body Dementia Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.
  • Lewy Body Dementia Pipeline Highlights - 2019, provides most up-to-date information on key pipeline products in the global Lewy Body Dementia market.
  • It covers emerging therapies for Lewy Body Dementia in active clinical development stages including early and late stage clinical trials.
  • The report provides Lewy Body Dementia pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.